07:00 AM EST, 11/13/2026 (MT Newswires) -- The European Medicines Agency's human medicines committee recommended AstraZeneca's (AZN.L) Baxfendy drug for market authorization, according to a Friday notice. The drug is intended for adults with poorly controlled arterial hypertension despite undergoing treatment with at least two blood pressure-lowering medicines. The positive opinion is based on clinical studies showing significant reductions in systolic and diastolic blood pressure. The drug remains subject to final approval by the European Commission.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.